Ashkan Afshin, MD ScD

Founder & CEO at Novelna

Ashkan Afshin, MD ScD has a diverse work experience that spans multiple positions and institutions. Ashkan is currently the Founder & CEO of Novelna, a position they have held since January 2023. Prior to this, they held the role of Co-Founder & CEO at Preverna Inc. starting in January 2021.

Before their leadership roles in the private sector, Dr. Afshin had a significant academic career. Ashkan served as an Associate Professor at the Institute for Health Metrics and Evaluation, starting in July 2021. Before that, they were an Assistant Professor from April 2017 to July 2021 and an Acting Assistant Professor from July 2015 to March 2017, all at the same institution.

Dr. Afshin also gained research experience during their time as a Postdoctoral Research Fellow at the Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy at Tufts University from September 2014 to June 2015, and at the Harvard T.H. Chan School of Public Health from 2010 to September 2014.

Overall, Dr. Ashkan Afshin has demonstrated expertise in both academia and the private sector, with a focus on health metrics, evaluation, and nutrition science.

Ashkan Afshin, MD ScD, completed their education in a chronological order. Ashkan began their studies at Tehran University of Medical Sciences where they obtained their MD degree in Medicine. It is uncertain when they started and completed this degree. Following this, they pursued their Master of Public Health (MPH) degree in Public Health at the Johns Hopkins Bloomberg School of Public Health, although the exact timeframe remains unknown. Afshin then continued their education at the Harvard T.H. Chan School of Public Health, where they obtained a Doctor of Science (ScD) degree in Epidemiology. Simultaneously, they earned another ScD in Global Health and Population. Additionally, they obtained a Master of Science (MSc) degree in Health Policy and Management during their time at Harvard.

Links

Peers

View in org chart

Timeline

  • Founder & CEO

    January, 2023 - present